Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, interventional study evaluating a neoadjuvant treatment approach for resectable esophageal squamous cell carcinoma. Participants receive camrelizumab in combination with chemotherapy and the JAK inhibitor Ivarmacitinib prior to esophagectomy. The goal is to see if this combination can increase tumor response and potentially improve surgical and survival outcomes. Eligible patients are adults 18–75 with resectable, stage II–IVA ESCC, good performance status, and no distant metastases. The study is conducted at Zhejiang University’s Second Affiliated Hospital in Hangzhou, China. Prior literature suggests potential synergy between ICIs, chemotherapy, and JAK inhibitors, but data in the neoadjuvant ESCC setting remain limited.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. signed informed consent;
2. patients age 18 to 75 years old
3. primary resectable, histologically confirmed esophageal squamous cell cancer;
4. Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).
5. ECOG PS 0-1.
6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist．

Exclusion Criteria:

1. with significant cardiovascular disease;
2. current treatment with anti-viral therapy or HBV;
3. Female patients who are pregnant or lactating;
4. history of malignancy within 5 years prior to screening;
5. active or history of autoimmune disease or immune deficiency;
6. signs of distant metastases.

Where it's running

• 2nd Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, China, China Recruiting

Study contacts

• Study coordinator: Zixiang Ｗu, M.D
• Email: zixiang0717@zju.edu.cn
• Phone: +8615268156132

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Interferon-gamma plus camrelizumab with chemotherapy before surgery for locally advanced esophageal squamous cell carcinoma

  This trial tests whether giving interferon-gamma with camrelizumab and chemotherapy before surgery helps patients with locally advanced esophageal squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Hefei Cancer Hospital of the Chinese Academy of Sciences · Hefei, Anhui and 1 other locations · NCT07787273

• Envafolimab with albumin-bound paclitaxel and carboplatin before surgery for resectable locally advanced esophageal squamous cell carcinoma

  This study tests whether adding envafolimab to albumin-bound paclitaxel and carboplatin before surgery helps people with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07266493

• Ivonescimab plus chemotherapy before surgery for resectable esophageal squamous cell cancer

  This study tests whether giving Ivonescimab together with chemotherapy before esophageal cancer surgery helps patients see better outcomes than surgery alone.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07244978

• Neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma

  This study is testing two different treatment plans for people with advanced esophageal cancer to see which one works better and is safer before surgery.

  Recruiting Phase 2/3 Army Medical Center of PLA · Chongqing, None Selected · NCT06354530

• Combining camrelizumab with chemotherapy for lung cancer treatment

  This study is testing if combining a new drug called camrelizumab with chemotherapy can help people with certain types of lung cancer before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06241807

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.